Pune, India, March 09, 2023 (GLOBE NEWSWIRE) -- The global diabetic nephropathy market size was valued at USD 2.38 billion in 2020. The market is estimated to rise from USD 2.49 billion in 2021 to USD 3.34 billion by 2028 at a 4.3% CAGR during the forecast period 2021 to 2028. Fortune Business Insights™ has deep-dived into these insights in its latest research report titled, “Diabetic Nephropathy Market, 2021-2028.”
According to the analysis, stakeholders will boost their product portfolios following the rise in the prevalence of obesity and diabetes across advanced and emerging economies. Escalating risk of blood sugar level and blood pressure will continue to augment the demand for nephropathy treatment in the ensuing period.
Key Industry Development
- Sun Pharmaceutical Industries Ltd announced that one of its wholly-owned subsidiaries inked licensing and supply agreements with Rockwell Medical Inc. to commercialize Rockwell's Triferic in India.
- FDA approved Bayer Ag’s Kerendia (finerenone) tablets to reduce the risk of decreasing kidney function, kidney failure, non-fatal heart attacks, cardiovascular death, and hospitalization due to heart failure in adults with chronic kidney disease associated with type 2 diabetes.
Request a free sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetic-nephropathy-market-102012
Report Scope
| Report Coverage | Details |
| Forecast Period | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR | 4.3% |
| 2028 Value Projection | USD 3.34 Billion |
| Base Year | 2020 |
| Market Size in 2021 | USD 2.49 Billion |
| Historical Data | 2017 to 2019 |
| No. of Pages | 120 |
Key Takeaways
- The kidney is the primary organ for diabetes-related microvascular injury.
- Technological advancements around the globe are promoting scientific developments for Diabetic Kidney Disease (DKD).
- Half of the adult population in the world will be overweight or obese by 2030 if the rate of obesity cases continues to rise.
- The WHO has dubbed diabetes the epidemic of the twenty-first century. According to the International Diabetes Federation's 2019 report, type 2 diabetes affects 463 million adults globally between the ages of 18 and 79.
Drivers and Restraints
Robust Pipeline Network to Augur Well for Market Forecast
Well-established players and emerging companies are banking on R&D for the rollout and launch of diabetic nephropathy drugs. Of late, drug approvals have picked pace, boosting the diabetic nephropathy market growth. For instance, in April 2021, the FDA gave a green signal to Farxiga (dapagliflozin) oral tablets from AstraZeneca to reduce the risk of kidney failure, kidney function, cardiovascular mortality, and hospitalization of individuals with chronic kidney disease who are at risk of disease progression. Besides, surging cases of obesity and diabetes are expected to remain instrumental in fueling the penetration of diabetic nephropathy treatment. According to the International Diabetes Federation 2019 report, the adult population with type 2 diabetes will reach 700 million by 2045.
Meanwhile, rigorous regulation requirements for approvals may mar the growth prospect during the forecast period.
Browse Complete Report Details: https://www.fortunebusinessinsights.com/diabetic-nephropathy-market-102012
Regional Insights
Stakeholders Prioritize North America as Diabetic Population Soars in the U.S.
Lately, the U.S. has witnessed an exponential rise in the diabetic population due to the need for nephropathy drugs and treatment. According to the CDC’s (Centers for Disease Control) National Diabetes Statistics Report for 2020, cases of diabetes rose to 34.2 million in the U.S. Moreover, approximately 15% of the U.S. adults were estimated to have chronic kidney disease, asserted the CDC in 2021. Leading companies are poised to further their investments across the U.S., fostering the North America diabetic nephropathy market share.
The Europe industry forecast will be bullish in the wake of the presence of prominent companies across the U.K., France, Italy, and Germany. Amidst surging cases of obesity and diabetes, major players are expected to expand their penetration. Citing data in 2021, AstraZeneca reported that Chronic Kidney Disease (CKD) affected nearly 47 million people in the EU. Stakeholders are slated to focus on their strategic approaches and bolster their footprint in the region.
Asia Pacific is expected to contribute a notable share toward the global market on the heels of robust government policies. Market participants expect China, Singapore, Australia, and India to spearhead the growth, largely due to strong and developing healthcare infrastructure. Hospital pharmacies and drug stores are expected to bolster their footprint across the region.
Report Coverage
The report elucidates drivers, restraints, opportunities, and trends and focuses on reshaping the global outlook. The report includes a SWOT analysis to provide an in-depth view of the market. It is prepared painstakingly through quantitative and qualitative research to offer a holistic view of the market. Further, primary interviews have been taken with major stakeholders and decision-makers. Primary data has been collected through telephonic conversations, emails, and questionnaires. Also, secondary sources include government websites, SEC filings, and press releases.
Buy Now - Diabetic Nephropathy Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/102012
Segments
Drug Class, Distribution Channel, and Region are Studied
In terms of drug class, the market is segmented into angiotensin receptor blockers, Angiotensin-Converting Enzyme (ACE) inhibitors, mineralocorticoid receptor antagonists, Sodium Glucose Cotransporter 2 (SGLT2) inhibitors, and others.
Based on distribution channel, the industry is segregated into drug stores & retail pharmacies, hospital pharmacies, and online pharmacies.
With respect to region, the market covers North America, Asia Pacific, Europe, and the Rest of the World.
Competitive Landscape
Stakeholders Emphasize Organic & Inorganic Strategies to Tap Markets
Key players are expected to focus on product portfolio expansion through investments in product launches, mergers & acquisitions, and R&D activities during the forecast period. Prominent players are likely to infuse funds into collaborations and technological advancements to expand footfall globally.
Major Players Profiled in the Market Report:
- Janssen Pharmaceuticals, Inc (U.S.)
- AstraZeneca (U.K.)
- Aurobindo Pharma Limited (India)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Bayer AG (Germany)
- Par Pharmaceuticals (U.S.)
Get a Quote: https://www.fortunebusinessinsights.com/enquiry/get-a-quote/diabetic-nephropathy-market-102012
FAQs
How big is the Diabetic Nephropathy Market?
The market is projected to grow from USD 2.49 billion in 2021 to USD 3.34 Billion by 2028, exhibiting a CAGR of 4.3% during the forecast period.
Which companies dominate the Diabetic Nephropathy Market?
The companies are Janssen Pharmaceuticals, Inc (U.S.), AstraZeneca (U.K.), Aurobindo Pharma Limited (India), Teva Pharmaceutical Industries Ltd (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Bayer AG (Germany), Par Pharmaceuticals (U.S.)
Detailed Table of Content:
- Key Insights
- Key Industry Developments
- New Product Launches
- Impact of COVID 19 on Global Diabetic Nephropathy Market
- Prevalence of Diabetic Nephropathy, By Key Countries
- Pipeline Analysis (Overall Analysis by Stage, Route of Administration, Molecule Type, Sponsor, etc.)
- Global Diabetic Nephropathy Market Analysis, Insights and Forecast, 2017-2028
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Drug Class
- Angiotensin Converting Enzyme (ACE) Inhibitors
- Angiotensin Receptor Blockers
- Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
- Mineralocorticoid Receptor Antagonists
- Others
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Rest Of The World
- North America Diabetic Nephropathy Market Analysis, Insights and Forecast, 2017-2028
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Drug Class
- Angiotensin Converting Enzyme (ACE) Inhibitors
- Angiotensin Receptor Blockers
- Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
- Mineralocorticoid Receptor Antagonists
- Others
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Market Analysis, Insights and Forecast – By Country
- U.S.
- Canada
-
-
- Insights on Usage of SGLT2 Inhibitors in CKD Stage 3 Patients
- Drugs Delaying Dialysis Onset: Analysis of Ongoing Studies
- List of Research & Educational Institutes in R&D
-
Continued...
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower, Baner
Mahalunge Road, Baner, Pune - 411045,
Maharashtra, India.
Phone:
U.S.: +1 424 253 0390
U.K.: +44 2071 939123
APAC:+91 744 740 1245
Email: sales@fortunebusinessinsights.com
